Abbott/Anesta Fentanyl Oralet promotion and distribution should become less restrictive -- FDA committee.

FENTANYL ORALET PROMO, DISTRIBUTION SHOULD BECOME LESS RESTRICTIVE, FDA's Anesthetic & Life Support Drugs Advisory Committee recommended Dec. 12. The committee unanimously agreed that promotion of the Abbott/Anesta narcotic analgesic (oral transmucosal fentanyl) should be allowed to extend to journal advertising and that distribution should go through the typical channels of wholesalers and distribution centers. "I personally can't see any benefit in putting such a restriction on the sponsor" for distribution and promotion, committee Chairman John Downs, MD, University of South Florida College of Medicine, said.